Citigroup
IDXG

Citigroup’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Citigroup’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5
Closed – – 7581
2017
Q1 		$0 Hold
5
– – ﹤0.01% 7420
2016
Q4 		$0 Buy
5
+3
+150% +$96 ﹤0.01% 7404
2016
Q3 		$0 Buy
+2
New +$55 ﹤0.01% 7271
2015
Q3 		– Sell
-1
Closed – – 7942
2015
Q2 		$0 Buy
+1
New +$139 ﹤0.01% 7888
2014
Q3 		– Sell
-1
Closed – – 7420
2014
Q2 		$0 Buy
+1
New +$461 ﹤0.01% 7419
2013
Q4 		– Hold
0
– – – 7231
2013
Q3 		– Hold
0
– – – 7085

Other funds holding IDXG

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Citigroup's IDXG Position: Q2 2017 in Review

Citigroup sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2017, closing a stake of 5 shares.

Citigroup first reported a position in IDXG in Q2 2014 and held it in 5 quarters. The position peaked at $0 in Q1 2017. 17 funds tracked by Wall St. Rank hold IDXG as of Q2 2017.

  • Citigroup reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Citigroup sold 5 Interpace Biosciences, Inc. Common Stock shares in Q2 2017.
  • Citigroup first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2014 and held it in 5 quarters.
  • Citigroup's Interpace Biosciences, Inc. Common Stock position peaked at $0 in Q1 2017.
  • 17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2017.

Based on Citigroup's 13F filing for Q2 2017, filed 11 Aug 2017.